LENZ · LENZ Therapeutics Inc
United States · RS rating 14 · As of 2026-11-03
| Price | 3.50 USD |
|---|---|
| 1-day change | +14.8% |
| RS rating (overall / 1M / 3M / 12M) | 14 / 50 / 18 / 6 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 15 / 6 / 10 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -96.6% |
| Sales growth Q/Q | -87.3% |
| Distance from 52-week high | +89.0% |
| Market cap (USD) | $286.9M |